This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
The deal includes upfront payments, milestone payments and ongoing royalties
IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate
Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
Ami Organics recently announced contract with global MNC for manufacturing of electrolyte for battery cells
According to Sun Pharma, the purpose of the strategic investment is to obtain access to the technology for certain compounds and territories while also fostering the development of novel pharmaceutical delivery systems.
The acquisition is done through cash consideration, by way of conversion of SAFE (Simple Agreement for Future Equity) investment of US$ 2 Million to Preferred A-1 Shares
Innovent also obtains an exclusive option to license in the future development, manufacturing and commercialization rights of SGB-3908
Innovent will supply sintilimab for the collaborated clinical trial
Subscribe To Our Newsletter & Stay Updated